Frost & Sullivan 2018 Award for Innovation in Artificial Intelligence for Aging Research and Drug Development
ROCKVILLE, Md. (PRWEB) June 20, 2018 -- Insilico Medicine has been awarded the prestigious 2018 North American Technology Innovation Award from Frost & Sullivan for its pioneering work in Artificial Intelligence for Aging Research and Drug Development. The accolade was awarded in recognition of Insilico Medicine’s “visionary capabilities in understanding the aging-related technology needs of academia, pharmaceutical companies, dietary supplement manufacturers, and cosmetics companies”.
“Recent breakthroughs in artificial intelligence are helping advance our fundamental understanding of aging and the age-related diseases and bridge biology and chemistry. What is less trivial is that aging research is helping us advance AI by making it more interpretable and all-encompassing. Age is a universal feature every living being has and the multi-modal deep-learned predictors of this feature allow us to integrate the many data types together from blood tests, transcriptomic, epigenetic and medical data to pictures, wearable data, EEG and many other data types. We can now extract the most important biological features, establish causality and look at the many diseases in the multiple therapeutic areas in a completely new way”, said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.
The field of artificial intelligence for longevity biotechnology is rapidly evolving and resulting in the new biomarkers and interventions. AI for aging research allows companies to build the business models that fit into the pharmaceutical industry and are both credible and sustainable. The award may signify the birth of a new industry described in the article by Alex Zhavoronkov. Insilico’s expertise in the generative adversarial networks and reinforcement learning resulted in the multiple industry collaborations, licensing deals and enabled it to attract funding from the expert strategic investors. The company recently announced a round of funding lead by the world’s largest and most respected research platform, WuXi AppTec, Pavilion Capital (Temasek Holdings), BOLD Capital Partners and a drug development company Juvenescence.
"Technology leadership in artificial intelligence for drug discovery and biomarker development, academic excellence, extensive collaborations with pharmaceutical and consumer companies, novel methods of attracting top talent, and increasing global reach have allowed Insilico Medicine to build a credible and sustainable business model in the nascent longevity biotechnology industry," noted Neelotpal Goswami. "In recognition of its pioneering research and ability to introduce novel products and solutions for age management, Frost & Sullivan is pleased to present it with the 2018 Technology Innovation Award."
Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables. Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan
Frost & Sullivan works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, they have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community.
About Insilico Medicine
Insilico Medicine is a next-generation artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research. It developed an end-to-end integrated artificial intelligence pipeline for every step of the pharmaceutical R&D process from hypothesis generation to biomarker development and target identification to compound generation, lead optimization, lead ranking, prediction of clinical trials outcomes and real-life evidence analysis. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging and is developing a range of tools for personalized medicine
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8
http://www.Insilico.com
Contact: Insilico Medicine
Qingsong Zhu, PhD
Insilico Medicine, Inc.
9601 Medical Center Dr, Suite 127
Rockville, MD 20850
Phone: 443 451 7212
Email: zhu(at)insilico.com
Contact: Frost & Sullivan
Samantha Park
Frost & Sullivan
Phone: 210 247 2426
Fax: 210 348 1003
Email: samantha.park(at)frost.com
Qingsong Zhu, Insilico Medicine, Inc., +1 4434517212, [email protected]
Share this article